Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mersana Therapeutics Inc (MRSN)

Mersana Therapeutics Inc (MRSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,344,336
  • Shares Outstanding, K 66,949
  • Annual Sales, $ 42,120 K
  • Annual Income, $ -28,210 K
  • 60-Month Beta 2.64
  • Price/Sales 32.22
  • Price/Cash Flow N/A
  • Price/Book 18.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.29
  • Number of Estimates 5
  • High Estimate -0.25
  • Low Estimate -0.35
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +17.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.49 +0.51%
on 08/11/20
23.86 -22.13%
on 07/21/20
-2.99 (-13.86%)
since 07/10/20
3-Month
9.00 +106.44%
on 05/14/20
24.97 -25.59%
on 07/08/20
+8.87 (+91.35%)
since 05/11/20
52-Week
1.32 +1,307.58%
on 11/04/19
24.97 -25.59%
on 07/08/20
+15.47 (+497.43%)
since 08/09/19

Most Recent Stories

More News
Mersana Therapeutics Receives FDA Fast Track Designation for XMT-1536 for the Treatment of Patients with Platinum-resistant Ovarian Cancer

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 18.58 (-7.47%)
Mersana Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update

- Presented positive interim expansion cohort data from XMT-1536 Phase 1 study at ASCO demonstrating a 35% objective response rate, including 10% complete response rate and 80% disease control rate in...

MRSN : 18.58 (-7.47%)
Mersana Therapeutics to Present at Upcoming Investor Conferences

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 18.58 (-7.47%)
4 Best-Performing Small-cap Biotechnology Stocks

Biotech stocks have been one of the strongest sectors since the coronavirus started impacting financial markets.  Here are 4 of the best-performing small-cap biotech stocks in 2020. Biotech stocks...

AKBA : 10.28 (-3.66%)
IBB : 131.88 (-2.22%)
MRSN : 18.58 (-7.47%)
VXRT : 10.75 (+14.42%)
TRIL : 8.33 (+2.84%)
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2020 Financial Results and Business Updates

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 18.58 (-7.47%)
Mersana's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Mersana Therapeutics.

MRSN : 18.58 (-7.47%)
Mersana Therapeutics Presents Preclinical Data from its Innovative Dolasynthen and Immunosynthen ADC Platforms at American Association for Cancer Research 2020 Virtual Annual Meeting

-- Preclinical data on multiple Immunosynthen STING-agonist ADCs show complete tumor regressions after a single dose, excellent tolerability and immune memory

MRSN : 18.58 (-7.47%)
Why Mersana Therapeutics (MRSN) Could Be Positioned for a Surge

Mersana Therapeutics (MRSN) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

MRSN : 18.58 (-7.47%)
Find Strong Buy Stocks for the Coronavirus Market Rally with this Screener

Find Strong Buy Stocks for the Coronavirus Market Rally with this Screener

MRSN : 18.58 (-7.47%)
CODX : 23.25 (-3.97%)
BGS : 28.81 (-1.57%)
Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Mersana Therapeutics, Inc., (Nasdaq:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 18.58 (-7.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade MRSN with:

Business Summary

Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

2nd Resistance Point 21.88
1st Resistance Point 20.23
Last Price 18.58
1st Support Level 17.71
2nd Support Level 16.83

See More

52-Week High 24.97
Last Price 18.58
Fibonacci 61.8% 15.94
Fibonacci 50% 13.14
Fibonacci 38.2% 10.35
52-Week Low 1.32

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar